Biomea Fusion to Participate in Bank of America Securities 2022 Healthcare Conference

Rhea-AI Summary

Biomea Fusion (Nasdaq: BMEA), a clinical-stage biopharmaceutical company, announced that CEO Thomas Butler will participate in a fireside chat at the Bank of America Securities 2022 Healthcare Conference. This event will occur on May 11, 2022, at 4:00 PM Pacific Time. Investors can access a live webcast of the chat, which will be available for 90 days post-presentation. Biomea Fusion focuses on developing covalent small molecules targeting genetically defined cancers and metabolic diseases, aiming to enhance treatment efficacy and patient outcomes.

News Market Reaction – BMEA

+14.36%

+14.36% Session move

In the trading session that priced this news, BMEA gained 14.36%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REDWOOD CITY, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, announced that Thomas Butler, Chief Executive Officer and Chairman of the Board, will participate in a fireside chat at the live Bank of America Securities 2022 Healthcare Conference. The fireside chat will take place on Wednesday, May 11^th at 4:00pm Pacific Time.

A live webcast of the fireside chat can be accessed at https://investors.biomeafusion.com/ and will be available for 90 days following the presentation.

About Biomea Fusion

Biomea Fusion is a biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response. The company is utilizing its proprietary FUSION™ System to advance a pipeline of covalent -binding therapeutic agents against key oncogenic drivers of cancer and metabolic diseases. Biomea Fusion’s goal is to utilize its capabilities and platform to become a leader in developing covalent small molecules in order to maximize the clinical benefit when treating various cancers and metabolic diseases.

Contact:

Van Sandwick
Director, Investor Relations & Corporate Development
vsandwick@biomeafusion.com
(650) 460-7759

FAQ

What is the date and time of Biomea Fusion's fireside chat at the Bank of America Securities 2022 Healthcare Conference?

The fireside chat is scheduled for May 11, 2022, at 4:00 PM Pacific Time.

Where can I watch the Biomea Fusion fireside chat live?

The live webcast of the fireside chat can be accessed at https://investors.biomeafusion.com/.

How long will the webcast of the Biomea Fusion fireside chat be available after the event?

The webcast will be available for 90 days following the presentation.

What is Biomea Fusion's focus in the biopharmaceutical industry?

Biomea Fusion is focused on discovering and developing covalent small molecules for genetically defined cancers and metabolic diseases.

What advantages do covalent small molecules offer according to Biomea Fusion?

Covalent small molecules provide greater target selectivity, lower drug exposure, and can drive deeper, more durable responses compared to conventional drugs.